Background: Vectors based on herpes simplex virus type 1 (HSV-1) can efficiently transduce hepatocytes in the mouse liver, and vector genomes can persist for at least 2 months. However, 24 hr after gene transfer, the number of cells that express the transgene decreases rapidly and no transduced cells are detectable after 7 days. In this study, we examined the capability of a helper virus-free HSV/AAV hybrid amplicon vector to extend transgene expression in hepatocytes in vivo. Materials and Methods: HSV-1 amplicon or HSV/ AAV hybrid amplicon vectors that express reporter genes from different transcriptional regulatory sequences were packaged into HSV-1 virions using a helper virus-free packaging system. To determine relative transduction efficiencies, vector stocks were titered on four different cell lines, including hamster kidney (BHK2 1) and human lung (Hs91 3T) fibroblasts, and mouse (G6Pase-/-) and human (NPLC) hepatocytes. After in vivo injection of vector stocks into mouse liver, tissue sections were examined for reporter gene expression and cellular inflammatory response. Blood samples were collected to measure serum transaminase levels as a biochemical index of liver toxicity.
Results: Expression of a reporter gene from liver-specific promoter sequences was consistently more effective in hepatic cells compared with fibroblasts, whereas the opposite was true when using an HSV-1 immediateearly promoter. Expression in hepatocytes in vivo was markedly longer from HSV/AAV hybrid vector compared with traditional HSV-1 amplicon vector: the number of transduced cells (-2% of all hepatocytes) remained stable over 7 days after injection of HSV/AAV hybrid vector, whereas no transduced cells were detected 7 days after gene transfer with standard HSV-1 amplicon vector. The rapid decline in reporter gene expression from standard amplicons was not solely caused by a B or T lymphocyte-mediated immune response, as it also occurred in RAG2-/-mice. Hepatocyte toxicity and cellular inflammatory effects associated with HSV/ AAV hybrid vector-mediated gene transfer were minimal, and readministration of vector stock proved equally effective in naive mice and in animals that received a first vector dose 4 weeks earlier.
Conclusions: HSV/AAV hybrid amplicon vectors support gene expression in vivo for considerably longer than do traditional HSV-1 amplicon vectors. Moreover, expression from these vectors does not provoke an overt inflammatory or immune response, allowing efficacious expression following repeated in vivo dosing. These characteristics suggest that such vectors may hold future promriise for hepatic gene replacement therapy.
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INTRODUCTION
Direct gene transfer into hepatocytes in vivo is highly desirable because the liver is the prime target of many metabolic disorders, infectious diseases, and cancers. Some metabolic disorders can be treated by periodic infusion of the deficient protein or by liver transplantation; however, all forms of current therapies have limitations. Since many of the inborn errors of metabolism, such as glycogen storage disease type la, familial hypercholesterolemia, familial hyperbilirubinemia (Crigler-Naijar syndrome), and hemophilia, are caused by monogenic defects, replacement of the defective gene in a subset of liver cells may be an effective treatment alternative.
Although nonviral delivery systems such as cationic liposomes can transfer genes into hepatocytes in vivo, vectors based on animal viruses are more effective because, as obligate parasites, they have evolved efficient strategies to enter host cells (1) . Consequently, a number of vector systems, including those based on retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus type 1 (HSV-1) have been developed. Retrovirus vectors have been extensively used as gene delivery vehicles because they can stably integrate into the genome of dividing cells; however, those vectors derived from Moloney murine leukemia virus (MoMLV) are ineffective for transferring genes directly into nondividing cells, such as hepatocytes in vivo (2) (3) (4) . Adenovirus vectors have been demonstrated to infect hepatocytes in vivo (5-7), but they support only short-term gene expression and inefficient gene transfer and, moreover, induce cytotoxic effects and a vigorous immune response (8) (9) (10) . AAV is an ideal candidate for vector development because this virus can stably integrate into the human genome (preferentially into chromosome 19ql3.3-qter) of dividing and nondividing cells while causing minimal cytopathic effects (11) . AAV vectors are created by substituting a transgene cassette for the viral rep and cap genes, which are flanked by the AAV inverted terminal repeats (ITRs). After infection of cells, these vectors can either persist in an episomal form (12, 13) or integrate into the cellular genome (14) (15) (16) . However, AAV vectormediated gene transfer into hepatocytes is inefficient (17, 18) , and the limited transgene capacity of these vectors (4.5 kb) does not allow incorporation of the viral rep gene, which encodes proteins that have important functions in the specificity and efficiency of integration into the cellular genome (19, 20 (27) . HSV-1 amplicons contain three types of genetic elements: (1) sequences from E. coli that allow plasmid propagation in bacteria; (2) the HSV-1 origin of DNA replication (orij) and cleavage/ packaging signal (pac), which allow replication and packaging of the amplicon into HSV-1 virions in the presence of HSV-1 helper functions; and (3) a transcription unit bearing the gene(s) of interest (28) . The cytotoxicity associated with HSV-1 amplicon vector-mediated gene transfer has been significantly reduced by the recent development of a helper virus-free packaging system, as it eliminates gene expression from helper virus conventionally used to package amplicons (23, 29, 30) . Although stability of gene expression is somewhat improved by the absence of helper virus alone (29), Johnston et al. (31) improved it further by developing an amplicon vector that combines the high infectibility and large transgene capacity of HSV-1 with the potential for episomal amplification and genome integration of AAV. This HSV/AAV hybrid vector is composed of (1) sequences from HSV-1 (oris and pac), (2) a transgene cassette flanked by the AAV ITRs, and (3) outside of this cassette, the AAV rep gene that may mediate amplification and genomic integration of ITR-flanked sequences. The hybrid vector is packaged efficiently into HSV-1 virions by using either helper virus-dependent or helper virus-free packaging systems (31) .
In this study, we evaluated the use of helper virus-free HSV-1 amplicon vectors for gene transfer into the liver. In particular, we examined the influence of different promoters on transduction efficiency in hepatocytes and fibroblasts, and the potential of HSV/AAV hybrid amplicon vectors to mediate extended transgene expression in mouse hepatocytes in vivo. Louis, MO) was digested with BglII and NotI, treated with T4 DNA polymerase, and the 1.0 kb fragment, which contains four copies of the human apolipoprotein E enhancer (apoE) fused to the human al-antitrypsin promoter (hAAT), was inserted into the EcoRV site of pBluescriptSK+ (pBsSK+). The resulting plasmid (pBapoEhAAT) was digested with NotI and HindIII, and the 1.0 kb fragment was inserted between the NotI and HindIII sites of HSV-1 amplicon plasmid pNSElac/i (C. Fraefel, unpublished data). This places the E. coli lacZ reporter gene under control of the apoEhAAT regulatory sequences (Fig. IC) . For pmalblac/i (10.4 kb) and pmalblac (9.7 kb), the 0.8 kb BamHI-BglII fragment from plasmid p145 (kindly provided by Dr. Katherine Ponder) which contains the mouse albumin promoter (34) was inserted into the BamHI site of pBsSK+. The resulting clone (pBmalb) was digested with NotI and HindIII, and the 0.8 kb fragment was inserted between the NotI and HindIII sites of either pNSElac/i or pNSElac (C. Fraefel, unpublished data), generating pmalblac/i and pmalblac, respectively. In both amplicons, the lacZ gene is under control of the mouse albumin promoter, but in contrast to pmalblac, pmalblac/i contains (similar to papoEhAAT) the a-globin intron downstream of the lacZ open reading frame (Fig. ID, E ). To construct pmalbe/placa (11.7 kb) and pmalbe/placb (1 1.7 kb), plasmid pBacalb (kindly provided by Dr. Frederick Boyce, MGH, Charlestown, MA) was digested with BamHI, blunt end repaired with T4 DNA polymerase, and the 2 kb fragment containing the mouse albumin enhancer (34) was inserted into the blunt end-repaired (T4 DNA polymerase) NotI site of pmalblac (see above). Two clones with the enhancer sequences in opposite orientations were isolated and designated pmalbe/placa and pmalbe/placb (Fig. IF 40 mM Tris-maleate (pH 6.5), 10 mM glucose-6-phosphate, 300 mM sucrose, and 3.6 mM lead nitrate. After exposure to 2% ammonium sulfide, the trapped lead phosphate was visualized as the colored lead sulfide (32) . For 13-galactosidase cytochemistry, transduced cells were fixed for 20 min with 4% paraformaldehyde in PBS, washed three times with PBS, and stained with 5-bromo-4-chloro-3-indolyl-,B-D-galactopyranoside (X-Gal) at 370C. After 6 hr, the cultures were washed twice with PBS, and 13-galactosidase-positive cells were counted under a magnification of X 10.
MATERIALS AND METHODS
Cell
Gene Transfer into Hepatocytes In Vivo
Animal studies were performed in accordance with guidelines issued by the Children's Hospital Animal Care and Use Committee. Normal mice (strain C57BL/6, 9-12 weeks; Charles River Laboratories, Wilmington, MA, and Jackson Laboratories, Bar Harbor, ME) or immunodeficient mice (RAG2-/-, 10 weeks; 36) were anesthetized by intraperitoneal injection of 0.15 ml of a solution consisting of 20% ketamine-HCl (Ketalar, 100 mg/ml; Parke-Davis, Morris Plains, NJ), 20% xylazine (Rompun, 20 mg/ml; Miles Inc., Shawnee Mission, KS), and 60% sodium chloride (0.9%; Abbott Laboratories, North Chicago, IL). The abdomen was opened through a midline FIG. 2. HSV-1 amplicon vector-mediated expression of glucose-6-phosphatase in cultured hepatocytes from G6Pase deficient mice pHSVmG6Pase and pHSVlac were packaged into HSV-1 virions by using the helper virus-free system. Glucose-6-phosphatase-deficient mouse hepatocytes (G6Pase-/-) in culture were infected with either (A) 10 ,tl or (B) 50 ,ul of pHSVmG6Pase or (C) 10 ,ul of pHSVlac stocks, and 24 hr later, stained for G6Pase enzyme activity. Scale bar, 40 ,um. incision, and 100 p,l vector stock was either injected directly into parenchyma of the left liver lobe or infused into the portal vein by using a 30 gauge needle. Blood samples (3 animals per group) were collected periodically and assayed for serum transaminase (ALT) levels and total bilirubin by colorimetric methodology. Following anesthesia and transcardial perfusion with PBS/4% paraformaldehyde, liver, lung and kidney (two to three animals per group) were collected at various time points after gene transfer. Organs were postfixed in 4% paraformaldehyde in PBS for 4 (32, 33, 37, 38) . To determine whether genetic replacement could correct the defect in cultured hepatocytes derived from mice with a targeted deletion of the G6Pase gene (32), we constructed HSV-1 amplicon vector pHSVmG6Pase (Fig. 1A) . G6Pase-/ -hepatocytes were infected with helper virus-free stocks of either pHSVmG6Pase or, as a control, pHSVlac (39; Fig. 1B ). Twentyfour hours later, G6Pase enzyme activity was clearly detected in pHSVmG6Pase-transduced cultures, but large volumes of vector stocks were required (Fig. 2) . The method used to visualize G6Pase enzyme activity disrupts the cell monolayer and forms a diffuse lead precipitate that does not allow determination of vector titer. However, the titers of stocks of amplicon vector pHSVlac (which expresses the E. coli lacZ gene from the HSV-1 immediate-early (IE) 4/5 promoter) obtained on infection of G6Pase -/ -cells was much lower compared with the titers obtained on BHK21 cells (see Table 1 and Fig. 3C ). This suggested that the G6Pase-/-cells were less susceptible to HSV-1 infection than the BHK21 cells, and/or that the HSV-1 IE 4/5 promoter, which controls the expression of the transgenes in pHSVmG6Pase and pHSVlac, was less active in G6Pase-/-cells than in BHI(21 cells. To explore the influence of the promoter, we compared the titers and transduction efficiencies seen between different cell lines on infection with HSV-1 amplicon vectors that express the E. coli lacZ gene from either the HSV-1 IE4/5 pro- Figure 3 show that pHSVlac (IE 4/5 promoter) transduced hepatic cells with a much lower efficiency than kidney or lung fibroblasts (-10-fold). In contrast, those vectors which contained liver-specific promoter sequences were consistently more effective in transducing hepatic cells than lung (Hs913T) fibroblasts (-10-to 100-fold), and equally or slightly less (2-fold) effective in transducing hepatic cells than kidney (BHK2 1) fibroblasts. The presence (pmalblac/i) or absence (pmalblac) of the a-globin intron, as well as the orientation of the albumin enhancer (pmalbe/placa and pmalbe/placb) had no apparent effect on the relative transduction efficiencies on the different cell lines. This experiment was repeated with at least two different preparations of each vector and consistently showed comparable relative transduction efficiencies. Moreover, the absolute transduction efficiencies (number of ,B-galactosidase-positive cells) on the different cells correlated with the amount of vector inoculum applied, whereas the relative transduction efficiencies remained virtually constant (not shown).
Previous reports demonstrated that HSV-1-based vectors, both recombinant viruses and ampli- (36) were injected with helper virus-free stocks of pHSvGN, which expresses the green fluorescent protein cDNA (gfp) from the cytomegalovirus (cmv) IE1 enhancer/promoter (Fig. 1H) . The titer of this vector was -40-fold higher than those of the papoEhAATlac/i or pmalbe/placa stocks used in the previous experiments. Twenty-four hours after injection of 2 X 107 t.u. (determined on BHK2 1 cells) of pHSvGN, -2% of all hepatocytes emitted green fluorescence. However, no positive hepatocytes were detected in the three animals examined at 7 days after gene transfer (Fig. 4A, B) .
HSV/AAV Hybrid Vector Extends Transgene Expression in Hepatocytes An HSV/AAV hybrid amplicon vector was previously reported to mediate extended transgene expression in cultured human glioma cells as compared with a standard HSV-1 amplicon (31) . In the following experiments we analyzed (1) the capability of this hybrid vector to extend transgene expression in hepatocytes in the mouse liver, and (2) the cytotoxic and inflammatory effects associated with gene delivery. C57BL/6 mice were injected intraparenchymally with either stocks of pHyRGN (HSV/AAV hybrid amplicon that expresses gfp from the cmv IE 1 enhancer/promoter; Fig. 11 injected liver lobes (Fig. 4C, D) . Remarkably, however, the number of green-fluorescent hepatocytes remained constant between days 1 and 7 after gene transfer with this hybrid amplicon vector (Fig. 4E, F) . Surprisingly, no green-fluorescent cells were detected in kidney or lung sections of any animal examined (not shown). Except for mild inflammatory infiltration in animals injected with either vector or vehicle alone, which was detected at day 1 and disappeared by day 7, no differences in gross hepatocellular architecture were apparent between injected and noninjected animals ( Fig. 5A-E) . These findings correlated with the ALT levels (a biochemical index of hepatocyte toxicity), which at day 1 were equally elevated in the animals injected with either vector or vehicle alone and returned to normal by day 7 (Fig. 5G) . Total bilirubin levels were within normal range in all animals (not shown). Fluorescent hepatocytes were still observed at 4 weeks following gene transfer with the hybrid vector, but the number of transduced cells, as well as the intensity of the fluorescence, was markedly lower than at day I or 7 (not shown).
Readministration of Amplicon Vector
The inefficient transduction of hepatocytes by standard adenovirus vectors upon readministration is related to the development of neutralizing antibodies to viral gene products (6, 8, 10 Fig. 3 ), the transduction efficiency of this vector was relatively low in hepatocytes in vivo. Nevertheless, the number of transduced cells was comparable in preinjected and naive animals (-2 (3-galactosidase-positive cells per mm2, Fig. 4G, H) ; moreover, the second vector dose did not cause more cellular infiltration (Fig. 5F) (24) (25) (26) . However, these studies used either recombinant HSV-1 vectors or amplicon vectors that were packaged using a helper virus, both of which induce cytotoxic effects and an immune response (27) . Although gene expression from the viral promoters was transient (<7 days) in these systems, a substantial number of vector genomes were still detectable even 2 months following gene transfer (24) . The helper virus-free amplicon system provides an efficient means for studying and identifying transcriptional regulatory sequences. In our study, the titration of vector stocks on different cell lines demonstrated that the transduction efficiency (the combination of infectivity and transgene expression) of a vector can vary dramatically from cell line to cell line. This cannot be attributed exclusively to differences in cell susceptibility, as expressing the lacZ reporter gene from liver-specific promoter sequences was consistently more effective (10-to 100-fold) in hepatic cells than in human lung fibroblasts, whereas the opposite was true when using the HSV-1 IE 4/5 promoter. Babiss et al. (42) (43, 44 In contrast to previous reports of HSV-1 and adenovirus vector-mediated gene transfer into the liver, the toxicity and inflammatory effects associated with gene delivery were minimal in our study. With respect to HSV-1, this is likely due to the absence of helper virus and HSV-1 gene expression (24, 27, 29, 30) . The vector caused no specific elevation in serum ALT or cellular inflammatory infiltration at 1, 7, or 28 days following gene transfer, even after readministration of vector. In contrast to standard adenovirus vectors which, because of the development of neutralizing antibodies, fail to transduce hepatoytes on readministration (6, 8, 10) , the helper virus-free amplicon vector proved equally effective in naive mice and in animals that received a first vector dose 4 weeks earlier.
In conclusion, these results demonstrate that helper virus-free HSV/AAV amplicon vectors are potentially useful vehicles for liver-directed gene transfer. The combination of advantageous features from different virus vector systems, such as the high infectibility and large transgene capacity of HSV-1 and the promise for episomal amplification and human chromosomal integration of AAV may synergistically improve the prospect of future gene therapy applications. The cytomegalovirus IE 1 promoter used in the hybrid vector has been shown to mediate robust, albeit transient, gene expression in hepatocytes in vivo (24) . In our study, reporter gene expression in hepatocytes was only occasionally detected at 4 weeks after infection with pHyRGN. We are currently exploring the use of liver-specific promoter elements in the context of this hybrid vector to further extend the efficiency of longterm gene expression. 
